장준(張俊) 교수

약학과[대학원] /약학부 /제약산업학과[대학원]

장준 프로필 사진
장준 교수는 약학과 소속 교수로 호흡기바이러스 감염 및 백신 연구의 권위자다. 포스텍 대학원에서 박사학위를 받았으며, 호흡기세포융합바이러스 및 인플루엔자 바이러스 백신 등에 대한 연구를 진행하고 있다. 현재까지 총 50여편의 논문을 SCI급 국제학술지에 발표했다. 
  • 약학연구소장
  • 약학관 B동 201호
  • 02-3277-2549
  • 연구관심분야
    • T 세포 면역, 범용 인플루엔자 백신, 호흡기 세포융합 바이러스
연구실적
  • Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus Clinical and Experimental Vaccine Research, 2019, v.8 no.1, 54~63
    KCI dColl.
  • Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus Antiviral Research, 2019, v.163, 19-28
    SCIE Scopus dColl.
  • Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection FRONTIERS IN IMMUNOLOGY, 2019, v.10, 567
    SCIE Scopus dColl.
  • Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus PLOS ONE, 2019, v.14 no.7, e0220196
    SCIE Scopus dColl.
  • Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (Gcf) PLOS ONE, 2014, v.9 no.4
    SCIE Scopus dColl.
  • Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier Acta Biomaterialia, 2014, v.10 no.11, 4606-4617
    SCIE Scopus dColl.
  • Intranasal Adenovirus-Vectored Vaccine for Induction of Long-Lasting Humoral Immunity-Mediated Broad Protection against Influenza in Mice JOURNAL OF VIROLOGY, 2014, v.88 no.17, 9693-9703
    SCIE Scopus dColl.
  • Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells Cell Reports Medicine, 2024, v.5 no.1, 101362
    SCIE Scopus dColl.
  • Vaccine Strategy That Enhances the Protective Efficacy of Systemic Immunization by Establishing Lung-Resident Memory CD8 T Cells Against Influenza Infection Immune Network, 2023, v.23 no.4, e32
    SCIE Scopus KCI dColl.
  • In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy Science Advances, 2022, v.8 no.3, eabj6901
    SCIE Scopus dColl.
  • A "Prime and Deploy" Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells IMMUNE NETWORK, 2021, v.21 no.4, e28
    SCIE Scopus KCI dColl.
  • Adenovirus Vectors: Excellent Tools for Vaccine Development Immune Network, 2021, v.21 no.1, 1-11
    SCIE Scopus KCI dColl.
  • Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant SCIENTIFIC REPORTS, 2021, v.11 no.1, 11981
    SCIE Scopus dColl.
  • IDO1 scavenges reactive oxygen species in myeloid-derived suppressor cells to prevent graft-versus-host disease Proceedings of the National Academy of Sciences of the United States of America, 2021, v.118 no.10, e2011170118
    SCIE Scopus dColl.
  • MHC Multimer: A Molecular Toolbox for Immunologists MOLECULES AND CELLS, 2021, v.44 no.5, 328-334
    SCIE Scopus KCI dColl.
  • Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy BIOMATERIALS SCIENCE, 2020, v.8 no.4, 1101-1105
    SCIE Scopus dColl.
  • Alveolar Macrophages Treated With Bacillus subtilis Spore Protect Mice Infected With Respiratory Syncytial Virus A2 FRONTIERS IN MICROBIOLOGY, 2019, v.10, 447
    SCIE Scopus dColl.
  • Plasmacytoid Dendritic Cells Contribute to the Production of IFN-beta via TLR7-MyD88-Dependent Pathway and CTL Priming during Respiratory Syncytial Virus Infection VIRUSES-BASEL, 2019, v.11 no.8, 730
    SCIE Scopus dColl.
  • Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus Clinical and Experimental Vaccine Research, 2019, v.8 no.1, 43~53
    KCI dColl.
  • Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice THERANOSTICS, 2018, v.8 no.3, 749-766
    SCIE Scopus dColl.
  • Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles FRONTIERS IN IMMUNOLOGY, 2018, v.9
    SCIE Scopus dColl.
  • Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant MICROBIOLOGY AND IMMUNOLOGY, 2018, v.62 no.3, 176-186
    SCIE Scopus dColl.
  • Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens FASEB JOURNAL, 2018, v.32 no.9, 4658-4669
    SCIE Scopus dColl.
  • Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen Nature Communications, 2018, v.9 no.1, 225
    SCIE Scopus dColl.
  • Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine FRONTIERS IN MICROBIOLOGY, 2018, v.9, 83
    SCIE Scopus dColl.
  • Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model FRONTIERS IN IMMUNOLOGY, 2018, v.9, 116
    SCIE Scopus dColl.
  • Basophil-derived IL-6 regulates TH17 cell differentiation and CD4 T cell immunity Scientific Reports, 2017, v.7
    SCIE Scopus dColl.
  • Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases PLOS ONE, 2017, v.12 no.1
    SCIE Scopus dColl.
  • Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection Journal of Microbiology, 2017, v.55 no.11, 900-908
    SCIE Scopus KCI dColl.
  • Universal vaccine against respiratory syncytial virus A and B subtypes PLOS ONE, 2017, v.12 no.4
    SCIE Scopus dColl.
  • miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation Cell Reports, 2017, v.20 no.11, 2598-2611
    SCIE Scopus dColl.
  • Baculovirus displaying hemagglutinin elicits broad cross-protection against influenza in mice PLoS ONE, 2016, v.11 no.3
    SCIE Scopus dColl.
  • Cholera Toxin Promotes Th17 Cell Differentiation by Modulating Expression of Polarizing Cytokines and the Antigen-Presenting Potential of Dendritic Cells PLOS ONE, 2016, v.11 no.6
    SCIE Scopus dColl.
  • Fas-Associated Factor 1 Negatively Regulates the Antiviral Immune Response by Inhibiting Translocation of Interferon Regulatory Factor 3 to the Nucleus MOLECULAR AND CELLULAR BIOLOGY, 2016, v.36 no.7, 1136-1151
    SCIE Scopus dColl.
  • In hot pursuit of the first vaccine against respiratory syncytial virus Yonsei Medical Journal, 2016, v.57 no.4, 809-816
    SCIE Scopus KCI dColl.
  • Role of PD-1 in regulatory T cells during chronic virus infection JOURNAL OF IMMUNOLOGY, 2016, v.196
    SCIE Scopus dColl.
  • Sublingual immunization with Japanese encephalitis virus vaccine effectively induces immunity through both cellular and humoral immune responses in mice MICROBIOLOGY AND IMMUNOLOGY, 2016, v.60 no.12, 846-853
    SCIE Scopus dColl.
  • The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination Scientific Reports, 2016, v.6
    SCIE Scopus dColl.
  • Co-transplantation of human fetal thymus, bone and CD34(+) cells into young adult immunodeficient NOD/SCID IL2R gamma(null) mice optimizes humanized mice that mount adaptive antibody responses CLINICAL IMMUNOLOGY, 2015, v.157 no.2, 156-165
    SCIE Scopus dColl.
  • Discrimination between Active and Latent Tuberculosis Based on Ratio of Antigen-Specific to Mitogen-Induced IP-10 Production JOURNAL OF CLINICAL MICROBIOLOGY, 2015, v.53 no.2, 504-510
    SCIE Scopus dColl.
  • Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines BMB REPORTS, 2015, v.48 no.10, 565-570
    SCIE KCI Scopus dColl.
  • Memory programming in CD8+T-cell differentiation is intrinsic and is not determined by CD4 help Nature Communications, 2015, v.6
    SCIE Scopus dColl.
  • PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8(+) T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8(+) T Cells JOURNAL OF IMMUNOLOGY, 2015, v.194 no.12, 5801-5811
    SCIE Scopus dColl.
  • Transplantation of human spleen into immunodeficient NOD/SCID IL2Rγnull mice generates humanized mice that improve functional B cell development Clinical Immunology, 2015, v.161 no.2, 308-315
    SCIE Scopus dColl.
  • Author Correction to Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection [Infection and Immunity, 82, 1, (2014) 132-139] Infection and Immunity, 2014, v.82 no.8, 3514
    SCIE Scopus dColl.
  • Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during Mycobacterium tuberculosis Infection INFECTION AND IMMUNITY, 2014, v.82 no.1, 132-139
    SCIE Scopus dColl.
  • [학술지논문] Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus ANTIVIRAL RESEARCH, 2019, v.163 no.1 , 19-28
    SCI
  • [학술지논문] Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection FRONTIERS IN IMMUNOLOGY, 2019, v.10 no.567 , 1-14
    SCIE
강의
  • 2024-2학기

    • 면역학 강의 계획서 상세보기

      • 학수번호 38958분반 01
      • 3학년 ( 3학점 , 3시간) 월 4~4 (약A400) , 수 3~3 (약A404)
      • 전공필수
    • 약학실습Ⅱ

      • 학수번호 38964분반 01
      • 3학년 ( 2학점 , 3시간) 화 6~7 (약A307)
      • 전공필수 약학전공 1~24
    • 약학실습Ⅱ

      • 학수번호 38964분반 02
      • 3학년 ( 2학점 , 3시간) 수 6~7 (약A307)
      • 전공필수 약학전공 25~48
    • 면역학 강의 계획서 상세보기

      • 학수번호 39063분반 01
      • 3학년 ( 3학점 , 3시간) 월 5~5 (약A400) , 수 5~5 (약A100-1)
    • 약학실습Ⅱ

      • 학수번호 39069분반 01
      • 3학년 ( 2학점 , 3시간) 월 6~7 (약A307)
      • 전공필수 미래산업약학전공 학번 95~111
    • 감염제어혁신신약개발

      • 학수번호 G16897분반 01
      • 학년 ( 3학점 , 3시간) 화 2~3 (약)
    • 바이오및화합물빅데이터이해와활용

      • 학수번호 G18091분반 01
      • 학년 ( 3학점 , 3시간) 금 4~5 (약)
  • 2024-1학기

    • 면역학 강의 계획서 상세보기

      • 학수번호 36201분반 01
      • 4학년 ( 3학점 , 3시간) 월 5~5 (포551) , 수 4~4 (약A404)
    • 분자생물학 강의 계획서 상세보기

      • 학수번호 38935분반 01
      • 2학년 ( 3학점 , 3시간) 화 4~4 (포) , 수 5~5 (161)
    • 약학실습Ⅱ

      • 학수번호 38964분반 01
      • 3학년 ( 2학점 , 3시간) 월 6~7 (약A307)
      • 전공필수 약학전공 49~71번
    • 약학실습Ⅱ

      • 학수번호 38964분반 02
      • 3학년 ( 2학점 , 3시간) 화 6~7 (약A307)
      • 전공필수 약학전공 72번 이후
    • 산업약학입문

      • 학수번호 39045분반 01
      • 2학년 ( 1.5학점 , 1.5시간) 목 6~6 (약A100-1)
    • 약학실습Ⅱ

      • 학수번호 39069분반 01
      • 3학년 ( 2학점 , 3시간) 수 6~7 (약A307)
      • 전공필수 미래산업약학전공 학번 112이후
    • 감염제어분자기전

      • 학수번호 G16858분반 01
      • 학년 ( 3학점 , 3시간) 금 4~5 (약)
  • 2023-2학기

  • 2023-1학기

  • 2022-2학기

    • 분자생물학

      • 학수번호 36205분반 01
      • 3학년 ( 3학점 , 3시간) 목 2~2 (약A100-1) , 금 3~3 (포552)
      • 팀티칭
    • 분자생물학

      • 학수번호 36205분반 02
      • 3학년 ( 3학점 , 3시간) 목 3~3 (약A100-1) , 금 4~4 (포552)
      • 팀티칭
    • 약학실습II

      • 학수번호 37106분반 01
      • 3학년 ( 1.5학점 , 3시간) 월 6~7 (약A307)
      • 전공필수 팀티칭, 학번 1-20
    • 약학실습II

      • 학수번호 37106분반 02
      • 3학년 ( 1.5학점 , 3시간) 화 6~7 (약A307)
      • 전공필수 팀티칭, 학번 21~40
    • 약학실습II

      • 학수번호 37106분반 03
      • 3학년 ( 1.5학점 , 3시간) 수 6~7 (약A307)
      • 전공필수 팀티칭, 학번 41-60
    • 임상면역학

      • 학수번호 37131분반 01
      • 4학년 ( 1.5학점 , 1.5시간) 목 6~6 (약A100-1)
    • Honors research

      • 학수번호 37803분반 01
      • 4학년 ( 1학점 , 1시간)
      • 팀티칭, 산업제약학과 02반과 합반
    • 감염제어혁신신약개발

      • 학수번호 G16897분반 01
      • 학년 ( 3학점 , 3시간) 금 6~7 (약)
    • 바이오및화합물빅데이터이해와활용

      • 학수번호 G18091분반 01
      • 학년 ( 3학점 , 3시간) 월 2~3 (약)
  • 2022-1학기

    • 면역학

      • 학수번호 36201분반 01
      • 4학년 ( 3학점 , 3시간) 화 4~4 , 목 4~4
      • 산업제약학과 02반과 합반
    • 면역학

      • 학수번호 36201분반 02
      • 4학년 ( 3학점 , 3시간) 화 4~4 , 목 4~4
      • 약학과 01반과 합반
    • 약학실습II

      • 학수번호 37106분반 01
      • 3학년 ( 1.5학점 , 3시간) 수 6~7 (약A307)
      • 전공필수 팀티칭/ 학번 61~80
    • 약학실습II

      • 학수번호 37106분반 02
      • 3학년 ( 1.5학점 , 3시간) 화 6~7 (약A307)
      • 전공필수 팀티칭/ 학번 81~100
    • 약학실습II

      • 학수번호 37106분반 03
      • 3학년 ( 1.5학점 , 3시간) 월 6~7 (약A307)
      • 전공필수 팀티칭/ 학번 101~120/산업제약학과 04반과 합반
    • 감염제어분자기전

      • 학수번호 G16858분반 01
      • 학년 ( 3학점 , 3시간) 수 2~3 (약A204)
  • 2021-2학기

    • 분자생물학

      • 학수번호 36205분반 01
      • 3학년 ( 3학점 , 3시간) 수 5~5 , 금 4~4
      • 팀티칭
    • 분자생물학

      • 학수번호 36205분반 02
      • 3학년 ( 3학점 , 3시간) 수 4~4 , 금 5~5
      • 팀티칭, 산업제약학과 03분반과 합반
    • 약학실습II

      • 학수번호 37106분반 01
      • 3학년 ( 1.5학점 , 3시간) 월 6~9 (약A307)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 1-22
    • 약학실습II

      • 학수번호 37106분반 02
      • 3학년 ( 1.5학점 , 3시간) 화 6~9 (약A307)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 23-43
    • 약학실습II

      • 학수번호 37106분반 03
      • 3학년 ( 1.5학점 , 3시간) 수 6~9 (약A307)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 44-65 / 산업제약학과 04분반과 합반
    • 임상면역학

      • 학수번호 37131분반 01
      • 4학년 ( 1.5학점 , 1.5시간) 목 5~5
    • 감염제어혁신신약개발

      • 학수번호 G16897분반 01
      • 학년 ( 3학점 , 3시간) 월 4~5
학력

포항공과대학교 이학박사(생명과학과)

서울대학교 이학사(미생물학과)

경력

국립암센터 선임연구원 2004-03-01 ~ 2005-08-31

UNIVERSITY OF VIRGINIA CARTER IMMUNOLOGY CENTER 1998-10-01 ~ 2001-10-31